Studies support diagnostic utility of molecular classification in difficult-to-diagno

[News]

bioTheranostics, Inc., developer of innovative oncology diagnostic tests and solution provider for metastatic cancer, today announced findings from two studies showing high diagnostic accuracy for CancerTYPE ID in determining the primary tumor site in high-grade, metastatic tumors. Results were reported at the 2012 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

More... (http://www.news-medical.net/news/20120602/Studies-support-diagnostic-utility-of-molecular-classification-in-difficult-to-diagnose-metastatic-cancer.aspx)